Gerresheimer reports strong first quarter

Düsseldorf (ots) -

- Crioss reference: Full press release is available at
http://www.presseportal.de/dokumente -

- First quarter revenues up 13.4% to EUR 342.3m
- Adjusted EBITDA grows by 29.6% to EUR 66.0m (Q1 2015: EUR 51.0m)
- Adjusted earnings per share surpasses prior year quarter by
72.1% to reach EUR 0.74
- Guidance for financial year 2016 confirmed

Gerresheimer AG, one of the leading partners to the pharma and
healthcare industry worldwide, made a successful start to financial
year 2016. "The first three months of the new year went well as
expected. We succeeded in generating strong revenue growth in the
first quarter. The strategic changes we initiated last year are
having a very positive impact on our business," said Uwe Röhrhoff,
CEO of Gerresheimer AG.

Pharmaceutical packaging manufacturer Gerresheimer boosted
revenues by 13.4% to EUR 342.3m in the first quarter of financial
year 2016 (December 1, 2015 to February 29, 2016). Part of the
revenue growth is accounted for by the business relating to plastic
packaging for prescription drugs acquired with the purchase of Centor
last year. This means Gerresheimer is now the leading supplier of
plastic containers for prescription tablets in the USA, having
already led the North American market in glass packaging for
parenteral drugs for a long time. On an organic basis, meaning
adjusted for exchange rate effects, acquisitions and divestments,
revenues increased in the same period by a substantial 4.4%. Revenues
with drug delivery devices such as asthma inhalers, insulin pens or
prefillable syringes increased significantly. As expected, primary
packaging glass sustained the favorable trend from preceding
quarters, displaying especially strong performance in injection
vials, ampoules and cartridges. Moulded glass product sales were also
up on an organic base, notably due to strong demand for glass
cosmetic packaging.

The first quarter of 2016 saw adjusted EBITDA increase by 29.6% to
EUR 66.0m. Adjusted EBITDA likewise came to EUR 66.0m on a constant
exchange rate basis. In the first quarter, the adjusted EBITDA margin
stood at 19.3%, significantly higher than the 16.9% recorded in the
prior-year period. Net income came to EUR 17.6m, up EUR 4.9m on the
prior-year quarter figure. Adjusted net income stood at EUR 25.0m in
the first quarter, compared with EUR 15.6m in the prior-year quarter.
Adjusted earnings per share climbed 72.1% year on year to EUR 0.74.

Gerresheimer incurred capital expenditure of EUR 13.7m in the
first three months (Q1 2015: EUR 13.9m). The Company purchased a site
for a new plastic pharmaceutical packaging plant in Brazil. At the